Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging

Abstract

Background:

New multiple sclerosis (MS) lesion activity on magnetic resonance imaging (MRI) can test immunomodulatory therapies in proof-of-concept trials. Comparably powerful endpoints to assess tissue protection or repair are lacking.

Objective:

The objective of this paper is to report sample-size calculations for assessment of new lesion recovery.

Methods:

In two sets of six active MS cases, new lesions were observed by monthly MRI for approximately 12 months. Averages and quartiles of normalized (proton density/T1/T2 weighted) and quantitative (T1/T2 and mean diffusivity maps for dataset 1, T2 and magnetization transfer ratio maps for dataset 2) measures were used to compare the lesion area before lesion appearance to afterward. A linear mixed-effects model incorporating lesion- and participant-specific random effects estimated average levels and variance components for sample-size calculations.

Results:

In both datasets, greatest statistical sensitivity was observed for the 25th percentile of normalized proton density-weighted signal. At 3T, using new lesions ⩾15 mm³, as few as nine participants/arm may be required for a six-month placebo-controlled add-on trial postulating a therapeutic effect size of 20% and statistical power of 90%.

Conclusion:

Lesion recovery is a powerful outcome measure for proof-of-concept clinical trials of tissue protection and repair in MS. The trial design requires active cases and is therefore best implemented near disease onset.

Keywords

MRI T2 lesions clinical trial design repair

Get full access to this article

View all access options for this article.

References

Lassmann

. Review: The architecture of inflammatory demyelinating lesions: Implications for studies on pathogenesis. Neuropathol Appl Neurobiol 2011; 37: 698–710.

Tomassini

Matthews

Thompson

. Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol 2012; 8: 635–646.

Trapp

Ransohoff

Rudick

. Axonal pathology in multiple sclerosis: Relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295–302.

Barkhof

Calabresi

Miller

. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256–266.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.

Altmann

Jasperse

Barkhof

. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 2009; 72: 595–601.

Healy

Valsasina

Filippi

. Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing–remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 1218–1223.

Henderson

Altmann

Trip

. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010; 133: 2592–2602.

Meier

Guttmann

. Time-series analysis of MRI intensity patterns in multiple sclerosis. Neuroimage 2003; 20: 1193–1209.

10.

Guttmann

Ahn

Hsu

. The evolution of multiple sclerosis lesions on serial MR. AJNR Am J Neuroradiol 1995; 16: 1481–1491.

11.

Gaitan

Shea

Evangelou

. Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 2011; 70: 22–29.

12.

van Waesberghe

van Walderveen

Castelijns

. Patterns of lesion development in multiple sclerosis: Longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998; 19: 675–683.

13.

McFarland

Stone

Calabresi

. MRI studies of multiple sclerosis: Implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult Scler 1996; 2: 198–205.

14.

van den Elskamp

Lembcke

Dattola

. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. Mult Scler 2008; 14: 764–769.

15.

Richert

Ostuni

Bash

. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001; 7: 49–58.

16.

Brown

Narayanan

Arnold

. Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis. Neuroimage 2012; 66: 103–109.

17.

Altmann

Button

Schmierer

. Sample sizes for lesion magnetisation transfer ratio outcomes in remyelination trials for multiple sclerosis. Mult Scler Relat Disord 2013; 3: 237–243.

18.

Vavasour

Laule

. Is the magnetization transfer ratio a marker for myelin in multiple sclerosis? J Magn Reson Imaging 2011; 33: 713–718.

19.

Mottershead

Schmierer

Clemence

. High field MRI correlates of myelin content and axonal density in multiple sclerosis—a post-mortem study of the spinal cord. J Neurol 2003; 250: 1293–1301.

20.

Schmierer

Altmann

Kassim

. Progressive change in primary progressive multiple sclerosis normal-appearing white matter: A serial diffusion magnetic resonance imaging study. Mult Scler 2004; 10: 182–187.

21.

Trapp

Peterson

Ransohoff

. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–285.

22.

Fisniku

Brex

Altmann

. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131 (Pt 3): 808–817.

23.

Sweeney

Shinohara

Shea

. Automatic lesion incidence estimation and detection in multiple sclerosis using multisequence longitudinal MRI. AJNR Am J Neuroradiol 2013; 34: 68–73.

24.

Shinohara

Crainiceanu

Caffo

. Population-wide principal component-based quantification of blood-brain-barrier dynamics in multiple sclerosis. Neuroimage 2011; 57: 1430–1446.

25.

Horsfield

Bakshi

Rovaris

. Incorporating domain knowledge into the fuzzy connectedness framework: Application to brain lesion volume estimation in multiple sclerosis. IEEE Trans Med Imaging 2007; 26: 1670–1680.

26.

Simon

Traboulsee

. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 2006; 27: 455–461.

27.

Nijeholt

Bergers

Kamphorst

. Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: A correlative study with conventional MRI, histopathology and clinical phenotype. Brain 2001; 124 (Pt 1): 154–166.

28.

Henderson

Barnett

Parratt

. Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009; 66: 739–753.

29.

Prineas

Parratt

. Oligodendrocytes and the early multiple sclerosis lesion. Ann Neurol 2012; 72: 18–31.

30.

Schmierer

Parkes

. Direct visualization of remyelination in multiple sclerosis using T2-weighted high-field MRI. Neurology 2009; 72: 472.

31.

Patrikios

Stadelmann

Kutzelnigg

. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129 (Pt 12): 3165–3172.

32.

Chen

Kuhlmann

Jansen

. Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage 2007; 36: 1152–1158.

33.

Arnold

Dalton

Schmierer

. Imaging of demyelination and remyelination in multiple sclerosis. In: Duncan

Franklin

RJM

(eds) Myelin repair and neuroprotection in multiple sclerosis. New York: Springer, 2013, pp.233–253.

34.

van den Elskamp

Knol

Vrenken

. Lesional magnetization transfer ratio: A feasible outcome for remyelinating treatment trials in multiple sclerosis. Mult Scler 2010; 16: 660–669.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.48 MB